News

Zymeworks to Share Insights at Key Investor Conferences

Zymeworks to Share Insights at Key Investor Conferences

Insights into Zymeworks' Upcoming Investor Conferences

Zymeworks Inc. (NASDAQ: ZYME) is poised to make significant waves in the biotechnology field as it announces its participation in various upcoming investor conferences aimed at showcasing its innovative approach to treating difficult-to-manage diseases. As a clinical-stage biotechnology company, Zymeworks is deeply committed to developing a diverse array of novel and multifunctional biotherapeutics.

Major Conferences Zymeworks Will Attend

Management at Zymeworks will participate in several noteworthy investor conferences, providing attendees with valuable insights into the company's research and strategies:

Piper Sandler Healthcare Conference

On December 3, Zymeworks' management team plans to engage in one-on-one meetings and present at the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for 1:30 PM Eastern Time in New York.

Citi's 2024 Global Healthcare Conference

Also on December 3, Zymeworks will take part in Citi's 2024 Global Healthcare Conference. The management team will engage in one-on-one meetings and participate in a panel discussion exploring 'Novel Antibody Mechanisms in Oncology' at 3:15 PM ET in Miami.

Evercore HealthCONx Conference

Following these key events, the management will attend the 7th Annual Evercore HealthCONx Conference on December 4, where they will continue to have one-on-one meetings and will engage in a fireside chat at 7:55 AM ET in Coral Gables.

Annual J.P. Morgan Healthcare Conference

Looking ahead to January 13-16, 2025, Zymeworks will participate in the 43rd Annual J.P. Morgan Healthcare Conference. During this event, it will hold one-on-one meetings and a corporate presentation on January 16 at 8:15 AM Pacific Time in San Francisco.

Research & Development Day and Future Innovations

In addition to participation in investor conferences, Zymeworks is set to present updates on its preclinical research programs at the upcoming Research & Development Day. This event will occur virtually and in-person on December 12, 2024, also in New York. Dr. Paul Moore, Zymeworks' Chief Scientific Officer, will lead the session.

What to Expect at the Research Event

The Research & Development Day will include:

  • Recent developments in Zymeworks' solid tumor-targeting antibody-drug conjugates and T-cell engager (TCE) molecules, featuring key opinion leaders with insights into ongoing research and clinical activities.
  • The nomination of a candidate from the Trispecific TCE platform as part of the company's '5 by 5' R&D strategy.
  • A comprehensive look at strategies for expansion into new therapeutic fields such as hematological cancers and autoimmune diseases, along with the progress of potential investigational new drug applications slated for 2026 and beyond.

About Zymeworks Inc.

Zymeworks is a global leader in the biotechnology sector, focused on the discovery, development, and commercialization of advanced biotherapeutics. Their mission centers around making a substantial impact on the lives of patients suffering from challenging cancers and other significant health issues. With a robust pipeline and an array of therapeutic platforms, Zymeworks operates a full-scale drug development engine that emphasizes precise engineering of antibody-based solutions.

Their significant achievements include the development of zanidatamab, a bispecific antibody targeting HER2, utilizing proprietary Azymetric™ technology. Zymeworks has forged partnerships with industry leaders like BeiGene, Ltd., and Jazz Pharmaceuticals to enhance development and commercialization efforts across various territories. Currently, zanidatamab is under evaluation in multiple clinical trials, demonstrating its potential as a leading treatment option for HER2-related cancers.

Investor and Media Contact Information

For those interested in learning more or attending the upcoming conferences and events, Zymeworks invites inquiries:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media Inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Frequently Asked Questions

1. What events is Zymeworks participating in?

Zymeworks will participate in several high-profile investor conferences and their own Research & Development Day.

2. When is the Research & Development Day?

The Research & Development Day is scheduled for December 12, 2024.

3. What is the significance of zanidatamab?

Zanidatamab is a bispecific antibody developed by Zymeworks targeting HER2 and is currently in clinical trials.

4. How can investors contact Zymeworks?

Investors can reach out to Shrinal Inamdar via email or phone for inquiries.

5. Where can I find more information about Zymeworks?

More information can be found on Zymeworks' official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Perennial Housing Group's Big Move into Affordable Housing

Updated Category News Views 54

Perennial's Ambitious Entry into the Affordable Housing Scene They say the real estate game's all about location, but when you’re diving into affordable housing, it's about necessity too. Perennial Housing Group, under the helm of seasoned CEO Gregory B. Jones, is kicking things off with a hefty acquisition—31 affordable housing communities spread across the Southeast...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 115

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 136

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
Foreigner to Rock Irvine with Night Ranger in 2027

Updated Category News Views 85

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 150

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Schools Reimagine Yearbooks with Interactive Archives

Updated Category News Views 133

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 250

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading
D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Updated Category News Views 129

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Continue Reading
Enjay Acquires New Method: A Strategic Synergy Unfolds

Updated Category News Views 116

Enjay's Bold Move into New Territory Here's a headline that doesn’t just flutter past like yesterday's news. Enjay Converters Ltd, straight from Cobourg, Ontario, has clinched a deal that looks like it might just shake things up a bit on the food packaging scene. They’ve bagged New Method Packaging LLC, another big player, but this time from the heartland of...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Shift in Investor Sentiment for JLL Stock

Updated Category News Views 139

Analyzing Investor Sentiment for Jones Lang LaSalle Jones Lang LaSalle's (JLL) stock has seen some interesting trends recently. Notably, the short percent of float has decreased by 31.32% since the last reporting period, indicating a significant shift in how traders are positioning themselves with respect to the stock. Currently, there are approximately 775 thousand...

Continue Reading
Innovative DN Series 300 and 350 Cash Dispensers from Diebold

Updated Category News Views 250

Revolutionizing Self-Service Banking with DN Series 300 and 350 Diebold Nixdorf, a forward-thinking leader in the world of banking technology, has introduced its latest innovations, the DN Series 300 and 350 cash dispensers. These state-of-the-art machines are transforming self-service banking experiences worldwide. The key to their advancement lies in the newly...

Continue Reading
Patient Safety at Risk: New Bill Threatens Consumer Protections

Updated Category News Views 303

Patient Safety at Risk: New Bill Threatens Consumer Protections Recent developments in California’s legislative assembly have raised serious concerns about patient safety following the proposal of a new bill aimed at reshaping how the Medical Board handles physicians with substance abuse issues. This bill, AB 408, is set to be discussed in the Assembly’s Business &...

Continue Reading
Exploring China's Sustainable Development at the 'Green Dream' Exhibition

Updated Category News Views 132

China's Green Dream Exhibition in Berlin Recently, an engaging photo exhibition titled "Green Dream: Themed Exhibition on the New Journey of Chinese Modernization" attracted international audiences in Berlin. This remarkable event highlighted China's ongoing efforts and achievements in sustainable development and modernization. Importance of Green Development Green...

Continue Reading
Innovative PLATE PROTECTOR Revolutionizes Weight Plate Usage

Updated Category News Views 267

Introducing the PLATE PROTECTOR for Enhanced Safety The world of fitness is evolving rapidly, and protecting our equipment is becoming increasingly crucial. The creator of the ingenious PLATE PROTECTOR aims to change how weight plates are treated in gyms and fitness centers. The innovative design presents an easy-to-use solution for safeguarding equipment and...

Continue Reading